{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:21:27Z","timestamp":1790180487009,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["neuromodulationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromodulation: Technology at the Neural Interface"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1111\/ner.12142","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T05:35:35Z","timestamp":1392183335000},"page":"472-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["In Vitro Stability of Low-Concentration Ziconotide Alone or in Admixtures in Intrathecal Pumps"],"prefix":"10.1016","volume":"17","author":[{"given":"Denis","family":"Dupoiron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chabert-Desnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Devys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Leynia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Boisdron-Celle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ner.12142_bib1","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","article-title":"Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/ner.12142_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-1403.2007.00128.x","article-title":"Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel","volume":"10","author":"Deer","year":"2007","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12142_bib3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1525-1403.2012.00507.x","article-title":"Polyanalgesic Consensus Conference 2012","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12142_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1525-1403.2012.00486.x","article-title":"Polyanalgesic Consensus Conference\u20132012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12142_bib5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1525-1403.2012.00449.x","article-title":"Polyanalgesic Consensus Conference\u20132012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses)","volume":"15","author":"Deer","year":"2012","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12142_bib6","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.36076\/ppj.2011\/14\/E283","article-title":"Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain","volume":"14","author":"Deer","year":"2011","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12142_bib7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/14656566.9.9.1575","article-title":"Ziconotide: an update and review","volume":"9","author":"Williams","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/ner.12142_bib8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1586\/14737175.6.10.1423","article-title":"Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain","volume":"6","author":"Wallace","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/ner.12142_bib9","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/ner.12142_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ALN.0b013e31821950c2","article-title":"Regulation of spinal substance p release by intrathecal calcium channel blockade","volume":"115","author":"Takasusuki","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1111\/ner.12142_bib11","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1523\/JNEUROSCI.14-08-04882.1994","article-title":"Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception","volume":"14","author":"Malmberg","year":"1994","journal-title":"J Neurosci"},{"key":"10.1111\/ner.12142_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-3565(25)38848-8","article-title":"Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia","volume":"269","author":"Chaplan","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ner.12142_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","article-title":"A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain","volume":"31","author":"Rauck","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12142_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/ner.12142_bib15","unstructured":"Administration, F.A.D. Xiconotide intrathecal infusion approval letter. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-060_Prialt_Approv.PDF, 2004."},{"key":"10.1111\/ner.12142_bib16","unstructured":"Agency, E.M. Ziconotide approval. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000551\/human_med_000989.jsp, 2005."},{"key":"10.1111\/ner.12142_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2011.10.002","article-title":"Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice","volume":"153","author":"Alicino","year":"2012","journal-title":"Pain"},{"key":"10.1111\/ner.12142_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/AJP.0b013e3181e017df","article-title":"Ziconotide combination intrathecal therapy: rationale and evidence","volume":"26","author":"Wallace","year":"2010","journal-title":"Clin J Pain"},{"key":"10.1111\/ner.12142_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpainsymman.2004.03.001","article-title":"Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery\u2014report of an expert panel","volume":"27","author":"Hassenbusch","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12142_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0885-3924(00)00206-2","article-title":"Polyanalgesic consensus conference 2000","volume":"20","author":"Portenoy","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12142_bib21","first-page":"140","article-title":"Douleur chronique canc\u00e9reuse et analg\u00e9sie intrath\u00e9cale: exp\u00e9rience de trois centres de lutte contre le cancer","volume":"12","author":"Dupoiron","year":"2011","journal-title":"Douleurs"},{"key":"10.1111\/ner.12142_bib22","first-page":"1213","article-title":"Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures","volume":"35","author":"Newton","year":"1978","journal-title":"Am J Hosp Pharm"},{"key":"10.1111\/ner.12142_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1023\/A:1008780126781","article-title":"Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit","volume":"22","author":"Gikic","year":"2000","journal-title":"Pharm World Sci"},{"key":"10.1111\/ner.12142_bib24","first-page":"1951","article-title":"Chemical incompatibility of parenteral drug admixtures","volume":"48","author":"McCarthy","year":"1974","journal-title":"S Afr Med J"},{"key":"10.1111\/ner.12142_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.36076\/ppj.2012\/15\/395","article-title":"Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol","volume":"15","author":"Dupoiron","year":"2012","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12142_bib26","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2008.01.007","article-title":"Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration","volume":"36","author":"Shields","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12142_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1525-1403.2005.00034.x","article-title":"Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration","volume":"8","author":"Shields","year":"2005","journal-title":"Neuromodulation"},{"issue":"Suppl1","key":"10.1111\/ner.12142_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1525-1403.2007.00130.x","article-title":"Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration","volume":"10","author":"Shields","year":"2007","journal-title":"Neuromodulation"},{"issue":"Suppl1","key":"10.1111\/ner.12142_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1403.2007.00131.x","article-title":"Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration","volume":"10","author":"Shields","year":"2007","journal-title":"Neuromodulation"},{"key":"10.1111\/ner.12142_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.36076\/ppj.2011\/14\/15","article-title":"Italian registry on long-term intrathecal ziconotide treatment","volume":"14","author":"Raffaeli","year":"2011","journal-title":"Pain Physician"},{"key":"10.1111\/ner.12142_bib31","unstructured":"Medtronic, Inc. Increased risk of motor stall and loss of or change in therapy with unapproved drug formulations. http:\/\/professional.medtronic.com\/wcm\/groups\/mdtcom_sg\/@mdt\/@neuro\/documents\/documents\/risk-motor-stall.pdf, 2012."},{"key":"10.1111\/ner.12142_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000542-200308000-00030","article-title":"Epidural, cerebrospinal fluid, and plasma pharmacokinetics of epidural opioids (part 2): effect of epinephrine","volume":"99","author":"Bernards","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1111\/ner.12142_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpain.2005.05.002","article-title":"A review of intrathecal morphine therapy related granulomas","volume":"10","author":"Miele","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1111\/ner.12142_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0885-3924(03)00144-1","article-title":"Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine\/opioid combinations","volume":"26","author":"Ackerman","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/ner.12142_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1526-4637.2002.02014.x","article-title":"Intrathecal clonidine in the treatment of intractable pain: a phase I\/II study","volume":"3","author":"Hassenbusch","year":"2002","journal-title":"Pain Med"},{"key":"10.1111\/ner.12142_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1529-9430(02)00199-7","article-title":"Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine","volume":"2","author":"Deer","year":"2002","journal-title":"Spine J"},{"key":"10.1111\/ner.12142_bib37","first-page":"371","article-title":"UPLC: a preeminent technique in pharmaceutical analysis","volume":"3","author":"Kumar","year":"2012","journal-title":"Acta Pol Pharm"},{"key":"10.1111\/ner.12142_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.talanta.2005.06.035","article-title":"Advantages of application of UPLC in pharmaceutical analysis","volume":"3","author":"Novakova","year":"2006","journal-title":"Talanta"},{"key":"10.1111\/ner.12142_bib39","unstructured":"Webster LR, Fakata KL. Ziconotide for chronic severe pain. Pract Pain Manag http:\/\/www.practicalpainmanagement.com\/treatments\/pharmacological\/non-opioids\/ziconotide-chronic-severe-pain."},{"key":"10.1111\/ner.12142_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.36076\/ppj.2013\/16\/415","article-title":"Physician response to medtronic\u2019s position on the use of off-label medications in the synchromed pump","volume":"5","author":"Rezai","year":"2013","journal-title":"Pain Physician"}],"container-title":["Neuromodulation: Technology at the Neural Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fner.12142","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715914601148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715914601148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ner.12142\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:51:07Z","timestamp":1761083467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094715914601148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1094715914601148"],"URL":"https:\/\/doi.org\/10.1111\/ner.12142","relation":{},"ISSN":["1094-7159"],"issn-type":[{"value":"1094-7159","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Stability of Low-Concentration Ziconotide Alone or in Admixtures in Intrathecal Pumps","name":"articletitle","label":"Article Title"},{"value":"Neuromodulation: Technology at the Neural Interface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ner.12142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}